<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05068284</url>
  </required_header>
  <id_info>
    <org_study_id>M20-371</org_study_id>
    <secondary_id>2021-002869-18</secondary_id>
    <nct_id>NCT05068284</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease</brief_title>
  <acronym>AIM-CD</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any&#xD;
      part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal&#xD;
      pain, weight loss, and fever. This study evaluates how safe and effective ABBV-154 is in&#xD;
      participants treated for moderately to severely active CD. Adverse events and change in the&#xD;
      disease activity will be assessed.&#xD;
&#xD;
      ABBV-154 is an investigational drug being evaluated for the treatment of CD. In the induction&#xD;
      period, there is a 1 in 5 chance that participants will be assigned to placebo. Depending on&#xD;
      the dose received in the induction period, there is a 1 in 2 or 1 in 3 chance that&#xD;
      participants will be assigned to placebo in the maintenance period. Around 265 participants&#xD;
      18-75 years of age with moderately to severely active CD will be enrolled in the study at&#xD;
      approximately 165 sites worldwide.&#xD;
&#xD;
      The study is compromised of a 12-week double-blind, placebo-controlled induction period,&#xD;
      followed by either a 12-week double-blind re-induction period for non-responders or a 40-week&#xD;
      double-blind placebo-controlled maintenance period for responders. In the maintenance period,&#xD;
      responders will be randomized to receive subcutaneous placebo or ABBV-154 in 2 different&#xD;
      doses every other week. Participants in the placebo group who are initial responders will&#xD;
      receive ABBV-154 in the maintenance period.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care due to study procedures. Participants will attend regular visits during the&#xD;
      study at a hospital or clinic. The effect of the treatment will be checked by medical&#xD;
      assessments, blood tests, checking for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 28, 2021</start_date>
  <completion_date type="Anticipated">March 7, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)</measure>
    <time_frame>Week 12 in the Induction Period</time_frame>
    <description>The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD &gt; 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission per Crohn's Disease Activity Index (CDAI)</measure>
    <time_frame>Week 12 in the Induction Period</time_frame>
    <description>The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. Clinical remission is defined as CDAI &lt; 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission per Average Daily Liquid or Very Soft Stool Frequency (SF) and Average Daily Abdominal Pain (AP) Score (SF/AP)</measure>
    <time_frame>Week 12 in the Induction Period</time_frame>
    <description>Clinical remission is defined as average daily liquid or very soft SF &lt;= 2.8 and not worse than Baseline and average daily AP score &lt;= 1 and not worse than Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Endoscopic Response per SES-CD</measure>
    <time_frame>Week 40 in the Maintenance Period</time_frame>
    <description>The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD &gt; 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission per CDAI</measure>
    <time_frame>Week 40 in the Maintenance Period</time_frame>
    <description>The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. Clinical remission is defined as CDAI &lt; 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission per SF/SP</measure>
    <time_frame>Week 40 in the Maintenance Period</time_frame>
    <description>Clinical remission is defined as average daily liquid or very soft SF &lt;= 2.8 and not worse than Baseline and average daily AP score &lt;= 1 and not worse than Baseline.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">265</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Induction Phase: ABBV-154 Randomized Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying doses of ABBV-154 as described in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Phase: ABBV-154 Randomized Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying doses of ABBV-154 as described in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Phase: ABBV-154 Randomized Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying doses of ABBV-154 as described in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Phase: ABBV-154 Randomized Dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying doses of ABBV-154 as described in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Phase: Randomized Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fixed dose placebo as described in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Re-Induction Phase: ABBV-154 Randomized Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying doses of ABBV-154 as described in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Re-Induction Phase: ABBV-154 Randomized Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying doses of ABBV-154 as described in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Phase: ABBV-154 Randomized Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose ABBV-154 every other week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Phase: ABBV-154 Randomized Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose ABBV-154 every other week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance Phase: Randomized Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fixed dose placebo every other week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-154</intervention_name>
    <description>Intravenous (IV) Infusion; Subcutaneous Injection</description>
    <arm_group_label>Induction Phase: ABBV-154 Randomized Dose A</arm_group_label>
    <arm_group_label>Induction Phase: ABBV-154 Randomized Dose B</arm_group_label>
    <arm_group_label>Induction Phase: ABBV-154 Randomized Dose C</arm_group_label>
    <arm_group_label>Induction Phase: ABBV-154 Randomized Dose D</arm_group_label>
    <arm_group_label>Maintenance Phase: ABBV-154 Randomized Dose A</arm_group_label>
    <arm_group_label>Maintenance Phase: ABBV-154 Randomized Dose B</arm_group_label>
    <arm_group_label>Re-Induction Phase: ABBV-154 Randomized Dose A</arm_group_label>
    <arm_group_label>Re-Induction Phase: ABBV-154 Randomized Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous (IV) infusion; Subcutaneous Injection</description>
    <arm_group_label>Induction Phase: Randomized Placebo</arm_group_label>
    <arm_group_label>Maintenance Phase: Randomized Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of Crohn's Disease (CD) for at least 3 months prior to Baseline of&#xD;
             the Induction Period.&#xD;
&#xD;
          -  Crohn's Disease Activity Index (CDAI) score 220 to 450 at Baseline of the Induction&#xD;
             Period.&#xD;
&#xD;
          -  Endoscopic evidence of mucosal inflammation as documented by an Simple Endoscopic&#xD;
             Score for Crohn's Disease (SES-CD) of &gt;= 6 for ileocolonic or colonic disease or&#xD;
             SES-CD of &gt;= 4 for isolated ileal disease as scored by a central reader. All eligible&#xD;
             scores must exclude the presence of narrowing component.&#xD;
&#xD;
          -  Demonstrated intolerance or inadequate response to one or more of the following&#xD;
             biologic agents: infliximab, adalimumab, certolizumab pegol, vedolizumab, natalizumab,&#xD;
             or ustekinumab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Participants with prior intolerance to adalimumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hoag Memorial Hosp Presbyterian /ID# 233555</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of CT /ID# 233542</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research - Inverness /ID# 233514</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452-4717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Medical Research Group /ID# 233506</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063-5737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group Naples /ID# 233829</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMIC Inc. Medical Research /ID# 233821</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 233824</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Gastroenterology /ID# 234278</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-State Gastroenterology /ID# 233805</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville /ID# 233766</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGG Group Co, Inc.Chevy Chase Clinical Research /ID# 233553</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Systems /ID# 233765</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 233763</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester /ID# 238516</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Medical Research /ID# 233826</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital /ID# 233823</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital /ID# 239312</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 234237</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Specialists /ID# 233825</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center /ID# 233920</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants /ID# 233764</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613-5028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants - Southlake /ID# 233744</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Research Institute, LLC /ID# 233730</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701-4464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants - Webster /ID# 233924</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center /ID# 233759</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital /ID# 233705</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Wien /ID# 234218</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck,Universitatsklinik fur Innere Medizin 1 /ID# 234217</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg-Universitätsklinikum der PMU (LKH) /ID# 234069</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Saint-Luc /ID# 232435</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege /ID# 232436</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ-Delta /ID# 232437</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospit /ID# 232468</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Tsaritsa Joanna - ISUL /ID# 234135</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic University Hospital EOOD /ID# 240003</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Medical Research Clinic (University of Calgary) /ID# 233838</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allen Whey Khye Lim Professional Corporation /ID# 233831</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5R 1W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Health /ID# 234277</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6K 4B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QE II Health Sciences Centre /ID# 233839</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott Shulman Medicine Professional Corporation /ID# 239567</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 2H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Digestive Disease Asso /ID# 234143</name>
      <address>
        <city>Vaughan</city>
        <state>Ontario</state>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Nice-Hopital L'Archet Ii /Id# 234226</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de SAINT ETIENNE - Hopital Nord /ID# 234225</name>
      <address>
        <city>St. Priest En Jarez</city>
        <state>Loire</state>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy - Hôpitaux de Brabois /ID# 234224</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hopital Saint-Louis /ID# 234227</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg /ID# 233719</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Mannheim /ID# 233716</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm /ID# 233531</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen /ID# 233529</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Regensburg /ID# 238702</name>
      <address>
        <city>Ratisbon</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxiszentrum fuer Gastroenterologie /ID# 233722</name>
      <address>
        <city>Grevenbroich</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 233527</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Berlin Westend /ID# 233718</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover /ID# 238804</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EUGASTRO GmbH /ID# 233717</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lueneburg /ID# 233720</name>
      <address>
        <city>Lueneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Ippokratio /ID# 231655</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chest Diseases of Athens SOTIRIA /ID# 231660</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion PA.G.N.I /ID# 231657</name>
      <address>
        <city>Heraklion</city>
        <state>Kriti</state>
        <zip>71500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Nikaia-Piraeus &quot;Agios Panteleimon&quot;- general hospital dytikis /ID# 231659</name>
      <address>
        <city>Pireaus</city>
        <zip>18454</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center /ID# 233458</name>
      <address>
        <city>Beer Sheva</city>
        <state>HaDarom</state>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center /ID# 233457</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>5239424</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center /ID# 238525</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center /ID# 233460</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center-Hebrew University /ID# 233518</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli /ID# 233380</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Rhodense/Presidio Ospedaliero di Rho /ID# 233386</name>
      <address>
        <city>Rho</city>
        <state>Milano</state>
        <zip>20017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Consorziale Policlinico /ID# 233387</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 233382</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova /ID# 233389</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital /ID# 239757</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon St.Mary's Hospital /ID# 233700</name>
      <address>
        <city>Daejeon</city>
        <zip>34943</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 233701</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center /ID# 233698</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum /ID# 232123</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Regional Hospital /ID# 238326</name>
      <address>
        <city>Newtown</city>
        <state>Wellington</state>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutt Hospital /ID# 238327</name>
      <address>
        <city>Lower Hutt</city>
        <zip>5010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital /ID# 238325</name>
      <address>
        <city>Otago</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planetmed Sp. z o.o. /ID# 238447</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>52-210</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WIP Warsaw IBD Point Profesor Kierkus /ID# 233533</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-728</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 238653</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Kant Baltic Federal University /ID# 234165</name>
      <address>
        <city>Kaliningrad</city>
        <state>Kaliningradskaya Oblast</state>
        <zip>236016</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uninova Medical Center /ID# 238775</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Oblast</state>
        <zip>198218</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Medical Center /ID# 238774</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirskaya Oblast</state>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perm Clinical Center of the Federal Medical and Biological Agency /ID# 234166</name>
      <address>
        <city>Perm</city>
        <state>Permskiy Kray</state>
        <zip>614109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University n.a I.M. Sechenov /ID# 238773</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 232373</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GASTRO I., s.r.o. /ID# 232372</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 232299</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruna</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau /ID# 232301</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz /ID# 232300</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia /ID# 234103</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital /ID# 234132</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital /ID# 234131</name>
      <address>
        <city>Taichung</city>
        <zip>407204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital /ID# 234134</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust /ID# 234188</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>E1 2ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust /ID# 234191</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde /ID# 234186</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0XH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 234187</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>ABBV-154</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

